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A B S T R A C T
Background
Extracorporeal membrane oxygenation (ECMO) is a complex procedure of life support in severe but potentially reversible respiratory
failure, used particularly in mature newborn infants. Although the number of babies requiring ECMO is small, and the ECMO policy
invasive and potentially expensive, its benefits may be high.
Objectives
To determine whether ECMO used for neonatal infants with severe respiratory failure is clinically effective and cost-effective compared
to a policy of conventional ventilatory support.
Search strategy
The Cochrane Neonatal Group Specialised Register, the Cochrane Controlled Trials Register, and MEDLINE were searched for 1974
to 2001.
Selection criteria
All randomised trials comparing neonatal ECMO to conventional ventilatory support.
Data collection and analysis
The authors independently evaluated the trials for methodological quality and appropriateness for inclusion in the Review (without
consideration of their results), and then independently extracted the data.
Main results
The three trials from the USA and one from the UK recruited clinically similar groups of babies. Two trials excluded infants with
congenital diaphragmatic hernias. In two, transfer for ECMO implied transport over a considerable distance. One study included an
economic evaluation. Two trials had follow up information.
All except the UK trial had very small numbers of patients. Two of the trials used conventional randomisation with low potential for
bias. The other two used less usual designs which have led to difficulties in their interpretation.
All four trials showed a strong benefit of ECMO on mortality (RR 0.44; 95% CI 0.31 to 0.61), especially for babies without congenital
diaphragmatic hernia (RR 0.33, 95% CI 0.21 to 0.53). Only the UK trial provided information about death or disability at one and
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four years, and showed benefit of ECMO at one year (RR 0.56, 95% CI 0.40 to 0.78), and at four years (RR 0.62, 95% CI 0.45 to
0.86). Overall nearly half of the children had died or were severely disabled at four years of age, reflecting the severity of their underlying
conditions. Based on economic analysis from the UK trial, the ECMO policy is as cost-effective as other intensive care technologies in
common use.
Authors’ conclusions
Apolicy of using ECMO inmature infants with severe but potentially reversible respiratory failure would result in significantly improved
survival without increased risk of severe disability amongst survivors. For babies with diaphragmatic hernia ECMO offers short term
benefits but the overall effect of employing ECMO in this group is not clear.
Further studies are needed to refine ECMO techniques; to consider the optimal timing for introducing ECMO; to identify which
infants are most likely to benefit; and to address the longer term implications of neonatal ECMO during later childhood and adult life.
P L A I N L A N G U A G E S U M M A R Y
Synopsis pending.
B A C K G R O U N D
Extracorporeal membrane oxygenation (ECMO) is a complex
technique for providing life support in severe but potentially re-
versible respiratory failure. The technique oxygenates blood out-
side the body, obviating the need for gas exchange in the lungs and,
if necessary, provides cardiovascular support. It is most commonly
used to support mature newborn infants, as preterm infants are
not suitable both because of the size of the cannulae required, and
because of their additional risk of intraventricular haemorrhage
associated with the use of heparin.
The concept arose as an off-shoot of cardiopulmonary by-pass
technology. Initially it was used to support adults but early re-
sults were poor. Similarly, early attempts to use ECMO in the
treatment of newborns were unsuccessful; cannula problems pro-
vided the greatest technical difficulty.However in 1975Bartlett re-
ported the first mature newborn treated successfully with ECMO
and other reports soon followed (Bartlett 1976). It subsequently
became clear that mature infants with persistent pulmonary hy-
pertension of the newborn (PPHN) were particularly suited to
ECMO since the better oxygenation and physiological stability
produced by ECMO improved pulmonary blood flowwithout the
risk of further barotrauma.
ECMO is an extremely invasive and technically involved pro-
cedure. Traditional ECMO uses two large gauge catheters, one
placed in a central vein and the other in a central artery (veno-
arterial or V-A). It is essential to achieve adequate flow rates (ap-
proximately 100 - 120 mls/kg/min) and as a result cannulae are
normally 12 - 14 French gauge. Blood is drained passively via the
venous catheter which is inserted into the internal jugular vein
and positioned in the right atrium. Blood then passes on to a
pump which maintains flow in the circuit. A ’bladder box’ and
servo system prevent the pump from working if venous drainage
becomes inadequate for any reason. Blood then passes to an oxy-
genator where a sweep gas passes in counter current to the blood.
The concentration of oxygen in the sweep gas can be adjusted de-
pending on the needs of the patient. Before re-entering the body
warming occurs in a heat exchange column. Blood is returned
via the common carotid artery at systemic pressure. This type of
ECMO is able to support both pulmonary and cardiac function.
More recently veno-venous (V-V) ECMO, which provides just
pulmonary support, has become popular. The particular, theoret-
ical, advantage of V-V ECMO is that the cerebral arterial blood
supply is not disrupted.
Whilst on ECMO additional gas exchange by the lungs is not
essential and therefore ventilation is normally reduced to ’rest’
settings. This is typically 5 - 10 cm H2O positive end expiratory
pressure and 10 to 20 breaths per minute but the approach does
vary from centre to centre. This strategy prevents any further lung
damage secondary to barotrauma but arrests the atelectasis which
might follow acutewithdrawal of respiratory support and enhances
clearance of secretions.
The point in an individual baby’s course at which ECMO should
be considered is debatable. A variety of physiological and clinical
parameters have beenused.However, over time, oxygenation index
(OI) of greater than 40 has probably become the most widely
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employed, where
OI =(Fi02) * (mean airway pressure cm H20) * 100 / PaO2 mm
Hg.
Although the absolute number of babies who reach this level of
severity is never likely to be large, the potential benefits of ECMO
may be extremely high. The policy is very invasive, however, and
because it is so labour intensive, it is likely to be expensive. Hence
there is a need for rigorous evaluation of its advantages and disad-
vantages to guide practice.
O B J E C T I V E S
To determine whether ECMO used for neonatal infants with se-
vere respiratory failure is clinically effective (especially in terms of
mortality and childhood disability) compared to a policy of con-
ventional ventilatory support. The policies will also be assessed in
terms of their relative resource use and cost-effectiveness.
R E S U L T S
Very few of the trials provided information about all the planned
outcomes, and only the UK and Syracuse trials had any follow up
information. Hence very few of the comparisons show data for all
the outcomes, either overall, or in the pre-specified subgroups.
Mortality
Death before discharge home (or to the end of data collection)
were the only outcomes reported for all four trials. For death before
discharge home, each of the four trials showed a strong benefit
of ECMO, but as the three US trials were all very small, the size
of effect (typical RR 0.44) was overwhelmingly determined by
the UK trial and the 95% CI was very tight (0.31 to 0.61), a
highly statistically significant benefit (p<0.00001). This can also
be expressed as a difference in rates of -0.32 (95% CI -0.44 to -
0.20), implying only three babies need to be treated with ECMO
rather than conventional ventilation to prevent one death. The
situationwas similar for deaths to the endof data collection (typical
RR 0.50, 95% CI 0.37 to 0.69; p=0.00003), although there were
some later deaths in the ECMO arm (from the trials with follow
up).
The majority of patients in these trials did not have congenital
diaphragmatic hernia as the primary diagnosis either because this
was an exclusion criterion (Boston and Syracuse) or because the
numbers with this primary diagnosis were relatively small (1/12
in the Michigan trial and 35/185 in the UK trial). The risk of
death by discharge for babies without this diagnosis was reduced
even more (typical RR 0.33, 95% CI 0.21 to 0.53; p<0.00001).
The results were similar for deaths to the end of data collection
(typical RR 0.41, 95% CI 0.27 to 0.63; p=0.00004). Even for the
35 babies in the UK trial with a primary diagnosis of congenital
diaphragmatic hernia, the risk of death was reduced (RR 0.72,
95% CI 0.54 to 0.06; p=0.03), but only five infants survived to
discharge, and only three children survived to four years of age,
all in the ECMO arm (17/17 of the infants in the conventional
management arm died before discharge).
Death or disability
Only the UK trial provided information about death or disability
at one and four years. This again showed an overall benefit of
ECMO at one year (RR 0.56, 95% CI 0.40 to 0.78; p=0.006),
and at four years (RR 0.62, 95% CI 0.45 to 0.86; p=0.004). The
benefit was evenmoremarked in the subgroup of childrenwho did
not have a primary diagnosis of congenital diaphragmatic hernia
at trial entry (RR at one year 0.45, 95% CI 0.28 to 0.72; p=
0.009), and at four years (RR 0.49, 95% CI 0.31 to 0.77; p=
0.002). The trend towards benefit for the children with congenital
diaphragmatic hernia at trial entry was much less marked (RR at
one year 0.78, 95% CI 0.61 to 1.00; p=0.05), and at four years
(RR 0.89, 95% CI 0.75 to 1.05; p=0.16), with only two children
alive and not severely disabled, both in the ECMO arm.
The Oxygenation Index at trial entry was used as a measure of
severity. The effect of a policy of ECMO by four years of age was
more marked in the less severe stratum of OI 40-60 (death or
severe disability at four years RR 0.52, 95% CI 0.31 to 0.85; p=
0.010) than the more severe stratum of OI >60 (death or severe
disability at four years RR 0.76, 95% CI 0.52 to 1.12; p=0.16)
although the trend is in the same direction.
Disability and impairment
Data from the UK trial at one year showed no clear trend in re-
lation to the risk of disability or impairment. Assessment of chil-
dren at one year is difficult to interpret and hence developmental
assessments are likely to have lacked precision. At 4 years much
more detailed information was available. Five children were lost to
follow up (3 in the conventional management group). Of the 60
randomised to ECMO and assessed at 4 years, 12 appeared normal
and 18 had signs of impairment without disability. The remaining
30 had signs of disability (3 severe). In the conventional arm 35
children were assessed, of whom 4 appeared normal with 9 having
signs of impairment without disability. The other 22 children in
this group were disabled but none were considered severe. The
data did not suggest that an increased risk of particular types of
adverse neurodevelopmental outcome (eg hemiplegia) was associ-
ated with either group.
Use of health services
Measures of resource use are analysed as continuous variables. All
four studies reported one or more of the defined resource use out-
comes, but the three American studies provided this information
for survivors only. In the UK trial, data were reported as medi-
ans (interquartile ranges (IQR)). These showed that a policy of
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ECMO compared to CM led to more days on ECMO (4 (3-7)
vs 0); more days on a ventilator (2 (0.5-4) vs 0 (0-5)); more days
on supplemental oxygen (3 (0-12.5) vs 0 (0-5)); fewer days on
oxygen at >90% (0.5 (0.5-1) vs 2 (1-5)); more days in hospital
before first discharge home or death (6 (1-11) vs 0.5 (0-6)); and
fewer hospital readmissions during the first year (0 (0-3) vs 1 (0-
7)). Some of the greater resource use in the ECMO arm is because
of the increased survival.
Costs and cost effectiveness
Only one study (UK 1996) included costs of health care over the
year, and this was reported separately (Roberts TE et al 1998). The
median cost/case for patients receiving extracorporeal membrane
oxygenation was £15276 (IQR £11242-£24786) (mean £20,826
) versus £3702 (IQR 2314-£9649) (mean £7,002) for patients
receiving conventional treatment (1994-95 UK sterling prices).
When compared to the gain in survival, the additional cost per
additional survivor at one year was £51,222, and the additional
cost per additional survivor without severe disability was £75,327.
Sensitivity analysis for uncertainty about transport costs, staffing
levels in neonatal and ECMO units, and odds of survival, found
that the range of cost per additional survivor could be between
£34,346 and £110,593. The purchasing power parity between
UK£ to US$ in 1996 was £0.644GB=$1US (OECD 2001).
D I S C U S S I O N
There was clear benefit for the ECMO policy in terms of reduc-
ing mortality and, although there were some later deaths in the
ECMO arm, the balance of benefits remains strongly in favour of
the ECMO policy for this outcome. Although there was a non-
statistically significant tendency towards more disability in the
ECMO group at one year, this was no longer the case by four
years of age in the UK trial. There was also an important benefit
of ECMOwhen considering the composite outcome of death OR
severe disability at both one and four years of age. Fuller details
of other outcomes from the UK trial shown in the accompanying
figures do not alter these conclusions, although numbers of chil-
dren with any one specific adverse outcome are small.
The diagnosis of severe but potentially reversible respiratory fail-
ure is not straightforward. Over the time that ECMO has been
available a variety of indices have been used in this role. All are
intended to identify babies with a high probability of death from
continued conventional therapy. The results of this review would
indicate that they achieve this aim. The various measures used to
identify suitable infants have not been compared but this seems
unnecessary given the randomised nature of the subsequent stud-
ies.
The invasive nature of ECMO has been the cause of much con-
cern. The potential for acute problems related to the ECMO cir-
cuit and the inevitable disruption to the cerebral circulation led
many to make the broad assumption that there was an inherent
risk attached to the use of ECMO which would inevitably result
in increased morbidity. These concerns have not been born out.
Since the risks are undeniable it would appear that the damaging
effect of prolonged exposure to aggressive conventional therapy
are even greater. It is important to note that only a minority of
all recruited infants could be considered normal survivors at four
years. Although ECMO has been considered as a single entity in
this comparison there was significant use of the veno venous tech-
nique in the UK study whilst this was not the case in earlier trials.
The majority of patients in these trials did not have congenital di-
aphragmatic hernia as the primary diagnosis either because thiswas
an exclusion criterion (Boston and Syracuse) or because the num-
bers with this primary diagnosis were small (1/12 in the Michigan
trial and 35/185 in the UK trial). Although the balance of benefit
was still in favour of the ECMO policy (17/17 of the infants in
the conventional management arm died before discharge), by the
age of 4 years, 16/18 of those in the ECMO arm had also died or
were severely disabled.
There was no evidence that the severity of illness as judged by an
OI of 40-60 or over 60 affected the benefit of the ECMO policy.
Although there is a clear benefit for the ECMO policy, overall
nearly half of the children had died or were severely disabled at
four years of age, reflecting the severity of their underlying condi-
tions. Nevertheless, based on the economic analysis from the UK
trial (Roberts et al, 1998), the ECMO policy is not only clinically
effective but also as cost-effective as other intensive care technolo-
gies in common use.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A policy of using ECMO in mature infants with severe but po-
tentially reversible respiratory failure would result in significantly
improved survival without any increased risk of severe disability
amongst survivors. A variety of indices can be used to define such
infants but the use of an oxygenation index of 40 seems the most
straightforward.
The situation for babies with diaphragmatic hernia is less clear
since, despite their common underlying anomaly, they do not rep-
resent a homogeneous group. It would appear that ECMO offers
short term benefits but the overall effect of employing ECMO
in this group is not clear. In the absence of a definitive study the
use of ECMO can only be recommended on clinical grounds i.e.
where it can be used to stabilise a baby thought to be potentially
viable but failing more conventional support.
Cost effectiveness is sensitive to the organisation of health care
for ECMO and intensive neonatal care. Lower cot occupancy and
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higher staff to cot ratios increase costs, as do long travel times and
distances.
Implications for research
Further studies are needed to refine ECMO techniques in an at-
tempt to reduce both short term risks (such as circuit failure) and
the damage that might result from physiological disruption. A for-
mal comparison of veno venous and veno arterial ECMO seems
particularly important in this regard.
The identification of suitable infants also merits further consid-
eration. At present infants are referred for ECMO when other
therapies have failed and the baby is continuing to deteriorate.
Outcomes might be improved by introducing ECMO earlier, ie
as soon as all other therapies have failed.
The longer term effects of neonatal ECMO (eg during later child-
hood, adolescence and adult life) remain unclear. Studies to ad-
dress these issues are clearly important if infants are going to con-
tinue to be offered this form of life support. A seven year follow
up is in progress for the UK trial.
The correct approach to themanagement of infants with diaphrag-
matic hernia is not known. Large randomised studies, with long
term follow up, are needed in order to establish both the best ap-
proach to acute management and the extent to which “normal
survival” is achievable with our present treatment options. There
is some uncertainty about what constitutes “present treatment op-
tions” and establishing the test arms would clearly be the first step
in developing such a study.
A C K N O W L E D G E M E N T S
Ellen Bifano, and Ann Johnson, Charlotte Bennett and Carole
Harris for unpublished data.
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